Close Menu

NEW YORK (GenomeWeb) – Diagnostics manufacturer Quidel reported after the close of the market on Wednesday that its fourth quarter revenues rose 15 percent year over year, due primarily to a steep rise in cardiac immunoassay revenues as well as increased sales of rapid immunoassay and molecular diagnostic products.

For the three months ended Dec. 31, 2018 Quidel reported revenues of $132.6 million, up from $114.9 million in Q4 2017, and beating the consensus analyst estimate of $132.1 million.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

A tissue sample from the 1960s harbors a near-complete sample of HIV, IFLScience reports.

A new bill would reshape the US National Science Foundation to include a focus on technological development, according to Science.

The Food and Drug Administration's decision to halt a SARS-CoV-2 study has drawn criticism, according to Stat News.

In Genome Biology this week: features affecting gut microbiome and parasite patterns, cellular interactions in lung tumor microenvironment, and more.

Jun
02
Sponsored by
NanoString

Core facilities support a broad range of scientific studies and must constantly integrate new technologies and analysis to underpin their users’ research. Areas for development include higher multiplex capabilities, greater quantification, correlation to other tools, as well as multi-omics. 

Jun
04
Sponsored by
Ovation

This webinar will discuss the current status of COVID-19 testing, treatment and other aspects of the current pandemic as they relate to getting this outbreak under control.